Welcome
Support Centre
21 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A Pilot Study to Assess Flutamide Monotherapy Compared With Maximal Androgen Blockade in Metastatic Prostate Cancer
ISRCTN ISRCTN92984394
ClinicalTrials.gov identifier
Public title A Pilot Study to Assess Flutamide Monotherapy Compared With Maximal Androgen Blockade in Metastatic Prostate Cancer
Scientific title
Acronym N/A
Serial number at source SCTO46
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Prostate cancer
Participants - inclusion criteria 1. Histologically confirmed prostate carcinoma 2. Skeletal metastases on bone scan, with radiological conformation if appropriate, or typical sclerotic metastases on X-ray
3. Life expectancy >6 months
4. Suitable for treatment by any of the study therapies
5. No previous hormonal therapy
6. Not currently receiving corticosteroids, spironolactone or aminoglutethamide
7. Adequate renal and hepatic function
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1994
Anticipated end date 30/09/1996
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions 1. Group A: Oral flutamide 250 mg three times daily
2. Group B: Oral flutamide 250 mg three times daily plus either orchidectomy or the lutenizing hormone releasing hormone (LHRH) analogue Zoladex (goserelin acetate). Zoladex is given by monthly injection at the dosage recommended by the manufacturer
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Schering-Plough Ltd (UK)
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Schering-Plough Ltd (UK)
  Address Schering-Plough House
Shire Park
  City/town Welwyn Garden City
  Zip/Postcode AL7 1TW
  Country United Kingdom
Date applied 19/08/2002
Last edited 29/05/2008
Date ISRCTN assigned 19/08/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central